MedTrace Logo

The Effectiveness of CD388 to Prevent Flu in an Influenza Challenge Model in Healthy Adults

NCT05523089 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 59

Last updated 2024-09-19

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the preventative antiviral activity of CD388, as compared to saline placebo, when administered as a single dose to healthy adult participants in a human viral challenge model of influenza.

Conditions

Interventions

DRUG

Saline placebo

Sterile normal saline for injection

COMBINATION_PRODUCT

CD388

CD388 liquid for injection

Sponsors & Collaborators

  • Janssen Pharmaceuticals

    collaborator INDUSTRY

  • Cidara Therapeutics Inc.

    lead INDUSTRY

Principal Investigators

  • Ozlem Equils, MD · Cidara Therapeutics Inc.

  • Arun Anandakumar, MD · hVIVO Services Limited

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-09-09
Primary Completion
2023-07-17
Completion
2023-07-17
FDA Drug
Yes

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05523089 on ClinicalTrials.gov